Stereotactic Body Radiotherapy for the Management of Prostate Cancer Local Recurrences
Recruiting
- Conditions
- C61Malignant neoplasm of prostate
- Registration Number
- DRKS00030837
- Lead Sponsor
- Europäisches Radiochirurgie Centrum München
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Histologically confirmed prostate cancer in the past medical history, radiographically verified local recurrence, status post prostatectomy and/or external beam radiotherapy
Exclusion Criteria
Lymph node metastases or distant metastases in the past medical history
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Cumulative incidence of new acute treatment-related genitourinary and gastrointestinal toxic effects = grade 2 according to CTCAE v5.0 three months after SBRT.
- Secondary Outcome Measures
Name Time Method Time to new androgen deprivation therapy, time to first metastasis, freedom from biochemical recurrence, quality of life per EPIC-26 and SF-12.